(202) 599-8435

FDA Extends Opioid Analgesic REMS to IR Products

Posted on Oct 10, 2017
By :

Food and Drug Administration (FDA) Commissioner Scott Gottlieb recently announced that the agency issued letters to 74 manufacturers of immediate release (IR) opioid analgesics, informing them that their medications will be subject to the same Risk Evaluation and Mitigation Strategy (REMS) requirements as extended release/long-acting (ER/LA) opioid analgesics. Read more here.

Print Friendly, PDF & Email
About the Author